SCHEMBL7147771

SCHEMBL7147771

Nc1nc(Sc2ccccc2)c(Br)c(-c2ccco2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 17/20 0.52
ADORA1 P30542 11/20 0.47
ADORA2B P29275 2/20 0.47
DHFR P00374 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 2/20 0.41
HPGD P15428 2/20 0.41
ALOX15 P16050 2/20 0.41
CASP1 P29466 2/20 0.41
PTPN7 P35236 2/20 0.41
RECQL P46063 2/20 0.41
BLM P54132 2/20 0.41
CASP7 P55210 2/20 0.41
KMT2A Q03164 2/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141937 0.82 ADORA2A (0.50) ADORA2AADORA1ADORA2BDHFRADORA3
SCHEMBL1553903 0.81 ADORA2A (0.60) ADORA2AADORA1ADORA2BDHFRKDM4E
SCHEMBL6449034 0.81 ADORA2A (0.67) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL7149150 0.81 HPGD (0.53) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL5036818 0.80 ADORA2A (0.49) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL7151572 0.78 KDM4E (0.48) ADORA2AADORA1ADORA2BDHFRADORA3
SCHEMBL7152501 0.74 ADORA2A (0.43) ADORA2AADORA1ADORA2BDHFRADORA3
SCHEMBL7143781 0.74 ADORA2A (0.54) ADORA2AADORA1ADORA2BDHFRADORA3
SCHEMBL30353605 0.74 ADORA2A (0.54) ADORA2AADORA1ADORA2BDHFRADORA3
SCHEMBL8995779 0.74 ADORA2A (0.54) ADORA2AADORA1ADORA2BDHFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.